Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Regulus Therapeutics Inc
RGLSCurrent price
2.76 USD
-0.04 USD (-1.43%)
Last closed
2.55 USD
Company
www.regulusrx.com
ISIN
US75915K3095
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
185 481 520 USD
Yield for 12 month
+9.52 %
1Y
3Y
5Y
10Y
15Y
RGLS
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 4224 Campus Point Court, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.83 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-21 152 000 USD
Current Quarter
–
Last Quarter
–
Key Figures RGLS
1 year
3 years
5 years
10 years
EBITDA
-49 693 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-54.42 %
PEG Ratio
-0.040
Return On Equity TTM
-95.00 %
Wall Street Target Price
10.83 USD
Revenue TTM
5 000 000 USD
Book Value
1.17 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
27 677.80 %
Dividend Yield
–
Gross Profit TTM
-35 367 000 USD
Earnings per share
-0.82 USD
Diluted Eps TTM
-0.82 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RGLS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RGLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:10
Payout Ratio TTM
–
Last Split Date
29.06.2022
Stock Valuation RGLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.66
Price Sales TTM
7.43
Enterprise Value EBITDA
0.57
Price Book MRQ
2.43
Financials RGLS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RGLS
For 52 weeks
0.83 USD
2.90 USD
50 Day MA
1.56 USD
Shares Short Prior Month
2 037 305
200 Day MA
1.54 USD
Short Ratio
1.36
Shares Short
2 658 100
Short Percent
5.08 %
BeatStart